Axsome Therapeutics,Inc. (NASDAQ:AXSM) Files An 8-K Other Events

ME Staff 8-k
-
0

Axsome Therapeutics,Inc. (NASDAQ:AXSM) Files An 8-K Other Events
Item 8.01.Other Events.

On February26, 2018, Axsome Therapeutics,Inc. (the “Company”) issued a press release announcing topline clinical trial results from a Phase 1 pharmacokinetic study of AXS-09, a novel, oral medicine consisting of chirally pure esbupropion and dextromethorphan being developed for the treatment of central nervous system disorders.

The full text of the press release is filed as Exhibit99.1 hereto and is incorporated herein by reference.

Item 8.01.Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number

Description

99.1

Press release dated February26, 2018.


Axsome Therapeutics, Inc. Exhibit
EX-99.1 2 a18-7071_1ex99d1.htm EX-99.1 Exhibit 99.1     Axsome Therapeutics Announces Primary Endpoint Met in Phase 1 Trial of Next Generation Product Candidate AXS-09 Containing Chirally Pure Esbupropion and Dextromethorphan   Chirally pure and stable single enantiomers of bupropion achieved   AXS-09 consists of esbupropion and dextromethorphan for CNS disorders   Esbupropion is the chirally pure S-enantiomer of bupropion   AXS-09 results in substantial increases in dextromethorphan plasma levels (p<0.0001)   NEW YORK,…
To view the full exhibit click here

About Axsome Therapeutics,Inc. (NASDAQ:AXSM)

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer’s disease (AD).